New! Get unlimited breaking news with a free Seeking Alpha account "
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call February 19, 2026 4:30 PM EST
Company Participants
Mark Johnson - Vice President of Investor Relations
Gene G. Kinney - President, CEO & Director
Chad Swanson - Chief Development Officer
Philip Dolan
Tran Nguyen - CFO & Chief Strategy Officer
Brandon Smith - Chief Operating Officer
Conference Call Participants
Michael DiFiore - Evercore ISI Institutional Equities, Research Division
Alexa Deemer - Cantor Fitzgerald & Co., Research Division
Jason Butler - Citizens JMP Securities, LLC, Research Division
Nevin Varghese - RBC Capital Markets, Research Division
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the Prothena Biosciences Fourth Quarter and Full Year 2025 Financial Results Conference Call. My name is Jeannie, and I will be your coordinator for today. [Operator Instructions]
I would now like to turn the presentation over to Mark Johnson, Vice President and Head of Investor Relations at Prothena. Please proceed.
Mark Johnson
Vice President of Investor Relations
Thank you, operator. Good afternoon, everyone, and welcome to today's call to review Prothena's business progress, fourth quarter and full year 2025 financial results and 2026 financial guidance. Please review the press release we issued earlier today, which is available on our website at prothena.com and is also attached to a Form 8-K filed today with the SEC. In addition, we are using supplemental slides, which are available on our Investors website, Events & Presentations section.
On today's call, Dr. Gene Kinney, our President and Executive Officer, will provide opening remarks, including an overview on Prothena's corporate strategy. Chad Swanson, our Chief Development Officer, will provide an update on our ongoing partnered clinical programs. Then Phil Dolan, our Vice President and Head of Discovery Research, will provide an update on our active preclinical programs. Tran Nguyen, our Chief Strategy Officer and Chief Financial Officer, will then discuss our 2025 financial results and 2026 financial guidance before turning it back to Gene
